First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Self-collection devices designed for ease of use and safety
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Subscribe To Our Newsletter & Stay Updated
